Das Gesundheitswesen, Table of Contents Gesundheitswesen 2025; 87(01): 17-20DOI: 10.1055/a-2419-8655 Editorial Strategien der Prävention Manfred Wildner Recommend Article Abstract Full Text References Literatur 1 Rose G. Sick individuals and sick populations. International Journal of Epidemiology 1985; 14: 32-38 2 Rose G. The Strategy of Preventive Medicine. Oxford Medical Publications, 1992, Siehe auch: Rose G, Khaw KT, Marmot MG. Rose's Strategy of Preventive Medicine. Oxford University Press; 2008 3 Doyle YG, Furey A, Flowers J. Sick individuals and sick populations: 20 years later. J Epidemiol Community Health 2006; 60: 396-398 4 Feigin VL, Martins SC, Brainin M. et al Twenty years on from the introduction of the high risk strategy for stroke and cardiovascular disease prevention: a systematic scoping review. Eur J Neurol 2024; 31: e16157 Epub 2023 Nov 27 5 Despang P, Schikora M, Doehner W. „Polypill“ in der kardiovaskulären Prävention – erfolgreich durch Vereinfachung? Neue Studienergebnisse zum Nutzen der Polypill-Strategie in der Primär- und Sekundärprävention. Inn Med (Heidelb) 2023; 64: 598-604 6 Rao S, Jamal Siddiqi T, Khan MS. et al. Association of polypill therapy with cardiovascular outcomes, mortality, and adherence: A systematic review and meta-analysis of randomized controlled trials. Prog Cardiovasc Dis 2022; 73: 48-55 7 Castellano JM, Pocock SJ, Bhatt DL. et al SECURE Investigators. Polypill Strategy in Secondary Cardiovascular Prevention. N Engl J Med 2022; 387: 967-977 8 Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419 siehe auch: A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003 Sep 13;327(7415):586. Erratum for: BMJ. 326:1419. 9 Sniderman AD, Thanassoulis G, Wilkins JT. et al Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated. J Am Heart Assoc 2018; Oct 2 7: e010049 10 Kaptoge S, Pennells L, De Bacquer D. et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health 2019; 7: e1332-e1345 11 World Health Organization. HEARTS. Technical package for cardiovascular disease management in primary health care. Risk-based CVD management. WHO, Geneva. https://apps.who.int/iris/bitstream/ handle/10665/ 333221/9789240001367-eng.pdf 12 Guideline for the pharmacological treatment of hypertension in adults. World Health Organization. 2021 Verfügbar unter https://iris.who.int/bitstream/handle/10665/344424/9789240033986-eng.pdf 13 Bahiru E, de Cates AN, Farr MR. et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev 2017; 14 Roshandel G, Khoshnia M, Poustchi H. et al Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet. 2019; Aug 24 394: 672-683 15 Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; Aug 1 317: 307-312 16 Windeler J. Der Check heiligt die Mittel. Wie die Vorbeugemedizin die Prävention mißhandelt. Observer Gesundheit. 23.10 2023 Verfügbar unter: https://observer-gesundheit.de/der-check-heiligt-die-mittel/ 17 Franzkowiak P. Prävention und Krankheitsprävention. In: Bundeszentrale für gesundheitliche Aufklärung (BZgA) (Hrsg.). Leitbegriffe der Gesundheitsförderung und Prävention. Glossar zu Konzepten, Strategien und Methoden. BZgA 2022; Verfügbar unter 18 Kisling LA, Das JM. Prevention Strategies. [Updated 2023 Aug 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Verfügbar unter. https://www.ncbi.nlm.nih.gov/books/NBK537222/ 19 Health promotion glossary of terms 2021. Geneva: World Health Organization; 2021. p.5. Verfügbar unter https://www.who.int/publications/i/item/9789240038349 20 Cholesterol Treatment Trialists’ (CTT) Collaboration Baigent C, Blackwell L, Emberson J. et al Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 13 376: 1670-1681 21 Brainin M. World Stroke Organization; Sliwa K; World Heart Federation. WSO and WHF joint position statement on population-wide prevention strategies. Lancet. 2020; Aug 22 396: 533-534 22 Brainin M, Feigin VL, Norrving B. et al. Global prevention of stroke and dementia: the WSO Declaration. Lancet Neurol 2020; 19: 487-488 23 Bétrisey S, Haller ML, Efthimiou O. et al. Lipid-Lowering Therapy and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc 2024; 20: e030714 24 Schwalm JD, McKee M, Huffman MD. et al. Resource effective strategies to prevent and treat cardiovascular disease. Circulation. 2016; 133: 742-755 25 Krishnamurthi R, George A, Merkin A. et al Can we stop the stroke tsunami? Mitigating the barriers, amplifying the facilitators. J R Soc N Z. 2020; Aug 4 52: 109-128 26 van Bruggen FH, de Haas EC, Zuidema SU. et al Time Gained to Cardiovascular Disease by Intensive Lipid-Lowering Therapy: Results of Individual Placebo-Controlled Trials and Pooled Effects. Am J Cardiovasc Drugs 2024; Aug 14 Epub ahead of print 27 Hansen MR, Hróbjartsson A, Pottegård A. et al Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials. J Gen Intern Med 2019; Aug 34: 1607-1614 28 World Health Organization. Tackling NCDs: 'best buys' and other recommended interventions for the prevention and control of noncommunicable diseases. World Health Organization; 2017. Verfügbar unter https://iris.who.int/handle/10665/259232 29 The Independent. Obituary: Prof. Geoffrey Rose (16.11.1993). Verfügbar unter https://www.independent.co.uk/news/people/obituary-professor-geoffrey-rose-1504672.html
